文献速递皮肤肿瘤

光声介观成像无创评估黑色素瘤深度

Non-invasive characterization of melanoma depth at single-cell resolution.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-07-03

本研究利用光声介观成像(RSOM)在单细胞分辨率下无创测量黑色素瘤的Breslow深度。在模型实验中优化RSOM并验证其单细胞成像能力,随后在9处病灶的初步临床研究中与组织病理学金标准比较,Breslow深度的拟合优度R²=0.886(p=0.0002)。RSOM可穿透皮肤超过3 mm,为无创确定肿瘤深度提供了新手段。

要点

  • RSOM可在单细胞分辨率下无创成像黑色素瘤,穿透深度超过3 mm。
  • 初步临床研究中,RSOM与组织病理学评估Breslow深度的R²=0.886(p=0.0002)。
  • RSOM有望辅助黑色素瘤的无创分期,但需进一步研究验证。

核心结论

  • RSOM提供了一种与Breslow深度测定相关的无创成像性能。
  • 需进一步工作确认这些发现并与其他无创方法比较。

研究设计与样本

  • 模型实验:使用体模优化RSOM并比较其测量单个黑色素瘤细胞浓度和直径的能力与金标准显微镜方法。
  • 初步临床研究:成像9处病灶(7例浅表扩散性黑色素瘤、1例良性发育不良痣、1例蓝痣),患者平均年龄56.2±12.5岁,另成像10处健康志愿者非病灶皮肤。
  • 采用线性回归比较RSOM测得的Breslow深度与临床标准,获得拟合优度(R²)和p值。

主要发现

  • 通过超宽带频率检测和优化照明波长,RSOM实现了单黑色素细胞分辨率的黑色素瘤无创成像,穿透皮肤超过3 mm。
  • RSOM与标准护理组织学评估Breslow深度的一致性为R²=0.886(p=0.0002)。

关键数值与推荐

  • RSOM与组织学评估Breslow深度的拟合优度R²=0.886(p=0.0002)。
  • RSOM穿透深度超过3 mm。

临床怎么用

  • RSOM可能作为无创工具辅助黑色素瘤的Breslow深度评估和分期。
  • 目前仅为初步研究,临床应用前需进一步验证。

局限性

  • 初步临床研究样本量小(9处病灶),需更大规模研究确认。
  • 未与其他无创方法进行比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Efficient staging and management of cutaneous melanoma, one of today's deadliest skin cancers, requires non-invasive determination of tumour depth (Breslow depth). However, current imaging technologies lack the necessary contrast or penetration to measure Breslow depth. OBJECTIVES: To determine if raster-scanning optoacoustic mesoscopy (RSOM) can fill this gap in dermatology. METHODS: We used phantoms to optimize RSOM for melanoma imaging and demonstrated its capability to image melanocytes at single-cell resolution in deep tissue. We then compared RSOM's ability to measure Breslow depth against the clinical standard in a pilot study. For the phantoms studies, we compared the ability of an optimized RSOM system to measure the concentration and diameter of single melanoma cells against gold-standard microscopy methods. For the pilot clinical study, we used linear regression to compare RSOM's Breslow depth against the clinical standard, obtaining the goodness of fit (R2) and the p-value. For the pilot clinical study, we imaged nine lesions: 7 superficially spreading melanomas, 1 benign dysplastic nevus and 1 blue nevus. The average age of the patients was 56.2 ± 12.5 years. We also imaged 10 non-lesional skin areas from healthy volunteers. RESULTS: By utilizing ultra-wideband frequency detection and optimized illumination wavelength, we show that RSOM achieves non-invasive imaging of melanoma at the resolution of single melanocytes, penetrating more than 3 mm into the skin. The agreement between RSOM and the standard-of-care histological assessment was R2 = 0.886 (p = 0.0002) for Breslow depth determination. CONCLUSIONS: RSOM provides non-invasive imaging performance that correlates with the Breslow depth determination. Further work is needed to confirm these findings and to test RSOM against other non-invasive methods.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Aguirre J, Gasteiger C, Hindelang B, et al. Non-invasive characterization of melanoma depth at single-cell resolution. J Eur Acad Dermatol Venereol. 2025. PMID: 40607870. doi:10.1111/jdv.20811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。